Home/Filings/4/0001754429-24-000004
4//SEC Filing

PLATT DAVID 4

Accession 0001754429-24-000004

CIK 0001445815other

Filed

Aug 19, 8:00 PM ET

Accepted

Aug 20, 5:10 PM ET

Size

18.5 KB

Accession

0001754429-24-000004

Insider Transaction Report

Form 4
Period: 2024-08-15
PLATT DAVID
DirectorCEO10% Owner
Transactions
  • Other

    preferred

    2024-08-19$0.81/sh+4,335,188$3,494,1624,335,188 total(indirect: by NDPD Pharma)
  • Other

    common

    2024-08-19$0.16/sh21,675,939$3,511,5020 total(indirect: by NDPD Pharma)
  • Other

    preferred

    2024-08-19$0.46/sh+776,817$354,22914,085,410 total(indirect: by NDPD Pharma)
  • Other

    common

    2024-08-19$0.00/sh411,300$4110 total(indirect: by Naomi Platt)
  • Other

    preferred

    2024-08-19$0.01/sh+8,605,455$43,0278,605,455 total
  • Purchase

    common

    2024-08-15$0.12/sh+1,592,921$197,52221,675,939 total(indirect: by NDPD Pharma)
  • Conversion

    preferred

    2024-08-19$0.02/sh+8,973,405$161,52113,308,593 total(indirect: by NDPD Pharma)
  • Other

    preferred

    2024-08-19$0.01/sh+82,260$41182,260 total(indirect: by Naomi Platt)
  • Other

    common

    2024-08-19$0.00/sh43,027,274$43,0270 total
Footnotes (4)
  • [F1]Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing.
  • [F2]A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock.
  • [F3]The shares were acquired through conversion of debt, issued under Rule 3(a)(9).
  • [F4]Total holdings by Naomi Platt, spouse of David Platt.

Issuer

BIOXYTRAN, INC

CIK 0001445815

Entity typeother

Related Parties

1
  • filerCIK 0001166440

Filing Metadata

Form type
4
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 5:10 PM ET
Size
18.5 KB